.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent data from the Dana-Farber Cancer Institute (DFCI) demonstrates the growing clinical significance of multi-cancer early detection tests. These liquid biopsies analyze circulating biomarkers to identify multiple malignancies simultaneously. As these technologies enter routine practice, clinicians must understand the diagnostic pathways and outcomes associated with positive test signals. The prospective case series evaluated patients between late 2023 and early 2025 to determine real-world performance metrics.
The study followed 14 patients with positive results from the Grail Galleri test. Notably, 78.6% of these participants received a confirmed cancer diagnosis, while 21.4% were identified as false positives. Specifically, 54.5% of confirmed cases involved solid tumors, and 45.5% were hematologic malignancies. Furthermore, the test demonstrated exceptional precision in identifying the cancer signal origin (CSO). Interestingly, over 90% of the detected malignancies currently lack standard screening guidelines. Consequently, these results suggest that multi-cancer early detection tests could fill critical gaps in traditional oncology screening.
Timely adjudication remains vital for patient outcomes and psychological well-being. Patients presented at the DFCI MCED clinic a median of 28 days after their test result. Subsequently, the multidisciplinary team achieved diagnostic resolution within a median of 20 days. Clinicians diagnosed six cancers at stage I or II, while five were found at stages III or IV. However, the study emphasizes that dedicated clinical programs are necessary to handle the complexity of positive signals. High diagnostic expertise ensures that patients receive quick and accurate evaluations following a positive screening.
In this clinical series, approximately 78.6% of patients with a positive signal had a confirmed cancer diagnosis. The remaining 21.4% were false positives, highlighting the need for specialized follow-up.
Specialized clinics can achieve diagnostic resolution in about 20 days. This rapid timeline helps reduce patient anxiety and allows for earlier treatment intervention.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.
References
O'Donnell EK et al. Diagnostic Outcomes Among Patients with Positive Multi-Cancer Early Detection Test Results. Cancer Res Commun. 2026 Feb 20. doi: 10.1158/2767-9764.CRC-25-0723. PMID: 41721625.
Grail. PATHFINDER 2 Study Results: Performance of the Galleri Multi-Cancer Early Detection Test. ESMO Congress. 2025.
ASCO Publications. Implementation and evaluation of multi-cancer early detection testing at the Dana-Farber Cancer Institute. J Clin Oncol. 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study on multi-cancer early detection tests shows 78.6% diagnostic accuracy and rapid resolution for positive signals at Dana-Farber Cancer Institute....
6 months ago
A clinical comparison of extravascular and subcutaneous implantable cardioverter-defibrillators, detailing patient selection, pacing capabilities, and implantation nuances.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
